Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: "John Feehally" Clear advanced filters

  • A relationship between IgA nephropathy (IgAN) and the mucosa has long been recognized with evidence from clinical observations and genetic studies suggesting that abnormalities in the IgA mucosal immune system could be a key element in the pathogenesis of IgAN. In this Review, Jürgen Floege and John Feehally describe current evidence that links the mucosa, in particular the gastrointestinal mucosa, and IgA produced in the bone marrow with IgAN.

    • Jürgen Floege
    • John Feehally
    Reviews
    Nature Reviews Nephrology
    Volume: 12, P: 147-156

  • Non-communicable diseases (NCDs) are taking center stage in global health policy. Intensive lobbying by the International Society of Nephrology has gained recognition for chronic kidney disease (CKD) as a major NCD. Continuing advocacy is needed for the health risk of CKD to be understood and opportunities for prevention and treatment grasped.

    • John Feehally
    News & Views
    Nature Reviews Nephrology
    Volume: 8, P: 12-13

  • Treatments administered to patients with primary IgA nephropathy (IgAN) and those with Henoch–Schönlein nephritis are largely based on opinion or weak evidence, and the recent KDIGO Clinical Practice Guidelines for Glomerulonephritis assigned low levels of evidence for the majority of recommendations and suggestions related to these two diseases. In this Review, Floege and Feehally describe an algorithm for structuring the treatment of IgAN depending on the clinical scenario, and discuss ongoing studies to investigate treatments.

    • Jürgen Floege
    • John Feehally
    Reviews
    Nature Reviews Nephrology
    Volume: 9, P: 320-327

  • Anti-CD20 therapy is increasingly being used in the treatment of various patterns of nephrotic syndrome in adults and children. However, its use is still based largely on observational studies and expert opinion. Well-designed randomized controlled trials are urgently needed to define the role of this expensive therapy.

    • John Feehally
    News & Views
    Nature Reviews Nephrology
    Volume: 10, P: 245-247

  • As IgA nephropathy (IgAN) is considered to result in part from autoimmune processes, B-cell depletion using rituximab might be a plausible therapy. However, a small randomized, controlled trial in patients at risk of progressive IgAN reports that this therapy failed to reduce proteinuria over 1 year and was associated with more adverse events per patient.

    • Jürgen Floege
    News & Views
    Nature Reviews Nephrology
    Volume: 13, P: 138-140

  • Corticosteroids are frequently used to treat patients with IgA nephropathy (IgAN) despite a paucity of data to support their use in individuals with substantially reduced renal function. A retrospective study provides evidence that these agents may slow the rate of decline in renal function in high-risk patients with IgAN.

    • Jürgen Floege
    News & Views
    Nature Reviews Nephrology
    Volume: 11, P: 319-320

  • Aspirin and other antiplatelet agents are widely used in patients with chronic kidney disease. However, their use is often based on data obtained in patients with normal renal function. A recent Cochrane Collaboration systematic review analysed the benefits and risks of these agents in patients with chronic kidney disease.

    • Jürgen Floege
    • Georg Schlieper
    News & Views
    Nature Reviews Nephrology
    Volume: 9, P: 314-316

  • Time-averaged proteinuria (TAP) is thought to be the most reliable predictor of outcomes in IgA nephropathy (IgAN). New data suggest that corticosteroids reduce TAP and presumably improve outcomes in IgAN, but increase the risk of adverse effects. Whether TAP is a good surrogate end point for clinical trials remains unclear.

    • Jürgen Floege
    • Thomas Rauen
    News & Views
    Nature Reviews Nephrology
    Volume: 12, P: 380-382

  • In this Viewpoint, five members of theNature Reviews Nephrologyadvisory board reflect on the progress and frustrations of the past decade in basic and clinical nephrology research. They comment on areas where effort and money should be invested and the challenges that remain to be overcome, as well as give their predictions for progress in the next decade.

    • Jürgen Floege
    • Robert H. Mak
    • Pierre Ronco
    Reviews
    Nature Reviews Nephrology
    Volume: 11, P: 677-687